SHP 627

Drug Profile

SHP 627

Alternative Names: FT 001; FT-011; SHP627

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fibrotech Therapeutics; University of Melbourne
  • Developer Shire
  • Class Anthranilic acids; Antifibrotics; Caffeic acids; Small molecules
  • Mechanism of Action Collagen inhibitors; Platelet-derived growth factor inhibitors; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic nephropathies; Focal segmental glomerulosclerosis; Heart failure; Kidney disorders

Most Recent Events

  • 08 Dec 2017 Occurx plans a clinical trial for Glaucoma in Australia (PO) (ACTRN12618000033246p)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diabetic-nephropathies in Australia (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Focal-segmental-glomerulosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top